Figures & data
Figure 1. Patient 1. A. Pleural and intrapulmonary metastases with pleural effusion, short before discontinuation of sorafenib. B. Progression of number and size of pulmonary metastases with increased pleural effusion, one week after discontinuation of sorafenib. C. Latest CT before the second stop of sorafenib. D. Progressive disease after discontinuation of sorafenib with pulmonary, pleural and lymph node metastases, pleural and pericardial effusion.
Figure 2. Patient 2. A. Pulmonary and lymph node metastases with pleural effusion. B. Increase lymphangitis carcinomatosis after discontinuation of sorafenib.
Figure 3. Patient 3. A. Pulmonary metastasis in left lung and limited thickness of the pleura of the left lung. B. Increased pleural metastases in left lung.
